A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less

Key Points

• This trial aims to evaluate the effectiveness of indinavir combined with nucleoside analogues in slowing HIV-1 disease progression in patients with low CD4 counts.
• Controlled trial comparing two treatment regimens: indinavir with zidovudine and lamivudine versus zidovudine and lamivudine alone.
• Target population included persons with HIV infection and CD4 cell counts of 200 per cubic millimeter or less.
• Participants had a history of prior exposure to zidovudine.
• Treatment with indinavir plus nucleoside analogues significantly slows disease progression compared to nucleoside analogues alone.
• Specific outcomes related to CD4 count improvement and clinical progression were observed, indicating a beneficial effect of the combination therapy.